Form D · Venture Capital Fund
SV Life Sciences Fund IV CF, L.P.
Boston, MA · CIK 0001877185
Offering snapshot reported Mar 25, 2022 · SEC filing
- Reported sold
- $421M Offering amount: $421M
- Investors reported
- 44 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 13, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2022 | Initial | $421,446,223 | No comparison | 44 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06b, 3C, 3C.1
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-438954
Source: Form D, filed Mar 25, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Houman Ashrafian | Executive |
| Michael Balmuth | Executive |
| Kate Bingham | Executive |
| Thomas Flynn | Executive |
| Eugene Hill | Executive |
| Paul La Violette | Executive |
| Greg Madden | Executive |
| Michael Ross | Executive |
| N/A Sv Life Sciences Fund Iv Cf (Gp), Llc | Executive |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
One Boston Place, Suite 3900
Boston, MA, 02108
Boston, MA, 02108